Answer
- The data, in processed form, can be accessed by the reporting physicians, thus also providing them with guidance for treatment. The more data is recorded, the better the quality of the information, which is also relevant for clinical practice (typical starting doses for specific patient groups, etc.).
- The online reporting system also offers straightforward access to relevant basic documents, such as treatment recommendations for various indications, prepared by the professional societies.
- Not least, by participating in the data collection programme, you are also helping to generate more evidence on the medical use of cannabis. In the medium term, this may help to ensure that more medicinal products of this kind are authorised by the regulatory authorities and reimbursed under compulsory health insurance. Further information (in French/German/Italian) can be found on the FOPH website: Revised legislation on medicinal cannabis products